Market Cap
$290.7M
LAB
STANDARD BIOTOOLS INC.
$0.7447 ▲ +2.01%
Prev close $0.7300Market cap$290.7M
12-mo target$1.35 (+81.3%)
High Impact Filing (7/10)26 New Institutional Positions19 Institutional Exits Industrials & Manufacturing
Snapshot
The big-picture read on LAB right now — valuation, ownership and activity at a glance.
Cap Size
Micro Cap
Inst. Holders
50 funds
Inst. Value
$108.9M
Inst. Activity
26 buys / 19 sells
Social Sentiment
67° Warm
SEC Reports
8
Press Releases
2
Price chart 30d +11.1%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 30, 2026 other
Standard BioTools Provides Update on Sale of Mass Cytometry Business
Standard BioTools Enters into New Purchase Agreement with Element Biosystems, a Subsidiary of GMT Ve
Aug 20, 2026 Insider
Egholm Michael surrendered for taxes 97,627 shares
President & CEO @ $0.6720 ($65.6K)
Aug 20, 2026 Insider
Mackay Sean surrendered for taxes 25,729 shares
SVP & Chief Business Officer @ $0.6720 ($17.3K)
Aug 20, 2026 Insider
Jul 29, 2026 SEC Kim Hanjoon Alex surrendered for taxes 28,195 shares
Chief Financial Officer @ $0.6720 ($18.9K)
Standard BioTools (LAB) filed an 8-K/A on July 29, 2026, attaching the full Share and Asset Purchase Agreement for the s
425 — Impact 4/10
Standard BioTools announced the sale of its Mass Cytometry business to Multiplex Bio for up to $10M, received ~$30M from
Impact 7/10
Jul 22, 2026 Event
Jul 20, 2026 SEC HSR Early Termination: Standard BioTools, Inc.; Treeline Biosciences, Inc.
The FTC granted early termination of the HSR Act waiting period for a transaction involving Standard
Standard Biotools (LAB) files S-4 for its all-stock merger with private biotech Treeline Biosciences, valuing Treeline a
S-4 — Impact 7/10
Analyst ratings buy % +17.5%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Nov 5, 2025 | TD Cowen | MAINTAIN | Hold | 56% |
| Feb 27, 2025 | Keybanc | DOWNGRADE | Sector Weight | 52% |
| Oct 31, 2024 | TD Cowen | MAINTAIN | Buy | 56% |
| Aug 1, 2024 | TD Cowen | MAINTAIN | Buy | 56% |
| Apr 16, 2024 | TD Cowen | INITIATE | Buy | 56% |
| Apr 4, 2024 | Jefferies | INITIATE | Buy | 53% |
| Jul 12, 2023 | Keybanc | INITIATE | Overweight | 52% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 2 | 2 | 2 | 0 | 0 | 67% | |
| Aug 1, 2026 | 2 | 2 | 2 | 0 | 0 | 67% | |
| Jul 1, 2026 | 2 | 2 | 2 | 0 | 0 | 67% | |
| Jun 1, 2026 | 2 | 2 | 2 | 0 | 0 | 67% | |
| May 1, 2026 | 2 | 2 | 3 | 0 | 0 | 57% | |
| Apr 1, 2026 | 2 | 2 | 3 | 0 | 0 | 57% | |
| Mar 1, 2026 | 2 | 2 | 3 | 0 | 0 | 57% | |
| Feb 1, 2026 | 2 | 2 | 3 | 0 | 0 | 57% |
Price targets
Where 1 covering analysts think LAB trades over the next 12 months.
$1.35 +81.3% upside Strong Buy
Current$0.7447 Low$1.35 Median$1.35 High$1.35 1 analysts
$1.35$1.35
Analyst rating None as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
67°
Warm
BearishNeutralBullish
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
8 SEC filing reports analyzed · 3 bullish, 2 bearish, 1 mixed, 2 neutral · avg impact 6.3/10.Plus 2 press releases.
NEUTRAL4254/10
Standard BioTools (LAB) filed an 8-K/A on July 29, 2026, attaching the full Share and Asset Purchase
Jul 29, 2026
MIXEDS-47/10
Standard Biotools (LAB) files S-4 for its all-stock merger with private biotech Treeline Biosciences
Jul 20, 2026
BULLISH4257/10
Standard BioTools (LAB) filed an S-4 registration statement for its all-stock reverse merger with Tr
Jul 20, 2026
BULLISH4257/10
Standard BioTools (LAB) announced a transformative all-stock reverse merger with private biotech Tre
Jun 8, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 30, 2026
other
Standard BioTools Provides Update on Sale of Mass Cytometry Business
Standard BioTools Enters into New Purchase Agreement with Element Biosystems, a Subsidiary of GMT Venture, After Determining GMT Venture’s Unsolicited
Sep 18, 2026
short_volume
Short Volume: LAB — 60.9% short (0.5M / 0.8M)
Short: 485,390 | Exempt: 415 | TRF Vol: 797,059 | Short Ratio: 60.9% | Off-exchange volume (dark pool + OTC)
Sep 9, 2026
short_volume
Short Volume: LAB — 63.2% short (0.8M / 1.3M)
Short: 821,782 | Exempt: 3,600 | TRF Vol: 1,300,826 | Short Ratio: 63.2% | Off-exchange volume (dark pool + OTC)
Sep 2, 2026
short_volume
Short Volume: LAB — 68.1% short (1.5M / 2.2M)
Short: 1,481,445 | Exempt: 0 | TRF Vol: 2,174,124 | Short Ratio: 68.1% | Off-exchange volume (dark pool + OTC)
Aug 20, 2026
short_volume
Short Volume: LAB — 61.1% short (0.6M / 0.9M)
Short: 571,546 | Exempt: 1 | TRF Vol: 935,344 | Short Ratio: 61.1% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.02 | $-0.02–$-0.02 | 75.0% | +42.9% | — | $0.0B | 1 |
| Next Q | $-0.02 | $-0.02–$-0.02 | -140.0% | +33.3% | — | $0.0B | 1 |
| Current FY | $-0.10 | $-0.10–$-0.10 | 50.0% | +37.5% | 0↑ 1↓ | $0.1B | 1 |
| Next FY | $-0.16 | $-0.16–$-0.16 | -60.0% | -23.1% | — | $0.1B | 1 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.020 | — |
| 7d ago | $-0.035 | +0.015 |
| 30d ago | $-0.035 | +0.015 |
| 60d ago | $-0.035 | +0.015 |
| 90d ago | $-0.035 | +0.015 |
Institutional ownership
Which big funds own LAB (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $108.9M total value (132,393,275 shares) as of 2026-Q2. Top holders: VIKING, VANGUARD, BlackRock,. Net buying activity: 26 institutions added/increased vs 19 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| VIKING GLOBAL INVESTORS LP | 58,651,170 | $48.3M | 44.3% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 12,252,998 | $10.1M | 9.3% | — |
| BlackRock, Inc. | 8,254,443 | $6.8M | 6.2% | TRIM -66.7% |
| Neuberger Berman Group LLC | 4,958,620 | $4.0M | 3.7% | — |
| Qube Research & Technologies Ltd | 4,820,463 | $4.0M | 3.6% | DOUBLED +584.3% |
| ROYCE & ASSOCIATES LP | 4,525,333 | $3.7M | 3.4% | ADD +50.6% |
| GEODE CAPITAL MANAGEMENT, LLC | 3,896,574 | $3.2M | 2.9% | TRIM -46.5% |
| MILLENNIUM MANAGEMENT LLC | 3,512,665 | $2.9M | 2.7% | ADD +67.1% |
| MORGAN STANLEY | 2,831,668 | $2.3M | 2.1% | TRIM -62.5% |
| D. E. Shaw & Co., Inc. | 2,818,026 | $2.3M | 2.1% | DOUBLED +1315.5% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | TRIM | 24,756,084 | 8,254,443 | -66.7% | $6.8M |
| Qube Research & Technologies Ltd | DOUBLED | 704,407 | 4,820,463 | +584.3% | $4.0M |
| ROYCE & ASSOCIATES LP | ADD | 3,005,529 | 4,525,333 | +50.6% | $3.7M |
| GEODE CAPITAL MANAGEMENT, LLC | TRIM | 7,289,336 | 3,896,574 | -46.5% | $3.2M |
| MILLENNIUM MANAGEMENT LLC | ADD | 2,102,015 | 3,512,665 | +67.1% | $2.9M |
| D. E. Shaw & Co., Inc. | DOUBLED | 199,084 | 2,818,026 | +1315.5% | $2.3M |
| CITADEL ADVISORS LLC | ADD | 1,225,310 | 2,348,570 | +91.7% | $1.9M |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | TRIM | 2,414,699 | 1,759,038 | -27.2% | $1.4M |
| STATE STREET CORP | NEAR_EXIT | 6,556,509 | 1,542,478 | -76.5% | $1.3M |
| NORTHERN TRUST CORP | TRIM | 2,454,235 | 791,526 | -67.7% | $651.2K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
9 insiders, 37 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 20, 2026 | Egholm Michael | President & CEO | TAX W/H | 97,627 | $0.6720 | $65.6K |
| Aug 20, 2026 | Mackay Sean | SVP & Chief Business Officer | TAX W/H | 25,729 | $0.6720 | $17.3K |
| Aug 20, 2026 | Kim Hanjoon Alex | Chief Financial Officer | TAX W/H | 28,195 | $0.6720 | $18.9K |
| Aug 3, 2026 | Egholm Michael | President & CEO | TAX W/H | 362,625 | $0.8680 | $314.8K |
| Jul 23, 2026 | Kim Hanjoon Alex | Chief Financial Officer | TAX W/H | 202,476 | $0.8950 | $181.2K |
| Jun 20, 2026 | Mackay Sean | SVP & Chief Business Officer | AWARD | 500,000 | — | — |
| Jun 18, 2026 | Cox Troy | Director | AWARD | 175,923 | — | — |
| Jun 18, 2026 | HIBBS KATHY L | Director | AWARD | 99,116 | — | — |
| Jun 18, 2026 | ELOI FENEL M | Director | AWARD | 99,116 | — | — |
| Jun 18, 2026 | ELOI FENEL M | Director | AWARD | 175,923 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for LAB.
Shares short
2,593,308
Settlement Sep 15, 2026
Change vs prior
-12.9%
Semi-monthly cycle
Days to cover
1.4
At avg daily volume
Of shares outstanding
≈0.7%
Estimate — not % of float
All LAB filing & press-release reports (10)
- 425 reportJul 29, 2026
- PRESS-RELEASE reportJul 28, 2026
- S-4 reportJul 20, 2026
- 425 reportJul 20, 2026
- 425 reportJun 8, 2026
- 8-K reportJun 8, 2026
- PRESS-RELEASE reportJun 8, 2026
- 8-K reportApr 24, 2026
- PRESS-RELEASE reportApr 21, 2026
- 8-K reportFeb 24, 2026